Advances in Molecular Mechanisms and Therapeutic Approaches in Lymphoproliferative Disorders
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 211
Special Issue Editors
Interests: leukemia; biomarker; drug resistance; CRISPR
Special Issue Information
Dear Colleagues,
Lymphoproliferative disorders comprise a group of several hematological malignancies characterized by excessive quantities of lymphocytes that cause monoclonal lymphocytosis, lymphadenopathy and bone marrow infiltration. In the last decades, promising advances have been made in the knowledge of the the molecular mechanisms on many of them, gaining insights into disease pathogenesis, diagnosis, prognosis and treatment. This understanding furthers to improve the clinical management of these diseases as well as treatment outcomes in patients.
We are pleased to invite you to contribute to the current Special Issue entitled “Advances in Molecular Mechanisms and Therapeutic Approaches in Lymphoproliferative Disorders” which aims to update biological and clinical aspects of lymphoproliferative disorders such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma, multiple myeloma, etc. We welcome original research as well as review articles addressing the state of the art and the future perspectives of this kind of hematologic malignancies, focusing preferentially on innovative research in biology and therapy.
We look forward to receiving your contributions.
Dr. María Hernández-Sanchez
Dr. Joaquín Martínez-López
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- leukemia
- lymphoma
- myeloma
- prognosis
- biomarker
- therapy
- drug target
- immunotherapy
- sequencing
- CRISPR
